# UNITED STATES
# SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

# FORM 8-K

**CURRENT REPORT**
**Pursuant to Section 13 or 15(d)**
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 12, 2022**

# MICROBOT MEDICAL INC.
**(Exact name of registrant as specified in its charter)**

| **Delaware** | **000-19871** | **94-3078125** |
|---|---|---|
| **(State or other jurisdiction of incorporation)** | **(Commission File Number)** | **(IRS Employer Identification No.)** |

**25 Recreation Park Drive, Unit 108**
**Hingham, Massachusetts 02043**
**(Address of Principal Executive Offices) (Zip Code)**

**Registrant's telephone number, including area code: (781) 875-3605**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
|---|---|---|
| Common Stock, $0.01 par value | MBOT | NASDAQ Capital Market |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure.**

On April 12, 2022, Microbot Medical Inc. (the "Company") posted updated presentation materials on its website.

The presentation materials can be accessed via the 'Investors' section, under 'Presentation + Resources,' of the Company's website at www.microbotmedical.com. The Company is not undertaking to update these presentation materials.

The presentation materials are furnished as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).

**Item 9.01. Financial Statements and Exhibits.**

***(d) Exhibits***

| Exhibit Number | Description |
|---|---|
| 99.1 | Presentation Materials |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**MICROBOT MEDICAL INC.**

By: */s/ Harel Gadot*
Name: Harel Gadot
Title: Chief Executive Officer, President and Chairman

Date: April 12, 2022

Exhibit 99.1


microbot medical
ACCESS-ABILITY FOR ALL™
HAREL GADOT
Chief Executive Officer, President, and Chairman of the Board of Directors
The LIBERTY system is currently under R&D and is not cleared for marketing or any clinical use in the US and ROW

# SAFE HARBOR STATEMENT

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, relating to future events or the future financial performance and operations of Microbot Medical, INC. Forward-looking statements, which involve assumptions and describe Microbot's intent, belief or current expectations about its business opportunities, prospects, performance and results, are generally identifiable by use of the words "may," "could," "should," "will," "would," "expect," "anticipate," "plan," "potential," "estimate," "believe," "intend," "project," "forecast," the negative of such words and other variations on such words or similar terminology. All statements other than statements of historical fact could be deemed forward-looking statements, including, but not limited to: risks inherent in the development and/or commercialization of potential products, including LIBERTY® and the self-cleaning shunt; the outcome of our studies to evaluate LIBERTY ® and the SCS and other existing and future technologies; uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals; uncertainty resulting from the COVID-19 pandemic; need and ability to obtain future capital; maintenance of intellectual property rights; our ability to find and develop applications for our technologies for other neurosurgical conditions besides hydrocephalus; our clinical development and other research and development plans and expectations; the safety and efficacy of our product candidates; the anticipated regulatory pathways for our product candidates; our ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of our product candidates and commercialize any approved products on our expected timeframes or at all; the content and timing of submissions to and decisions made by the U.S. Food and Drug Administration and other regulatory agencies; our ability to leverage the experience of our management team; and any statements or assumptions underlying any of the items mentioned. These forward-looking statements are not guarantees of future performance and by their nature involve known and unknown risks and uncertainties that may cause actual opportunities, prospects, performance and results to vary from those presented in this document, and those variances may be material. In evaluating such statements, prospective investors should carefully consider the various risks and uncertainties identified in Microbot's public filings with the Securities and Exchange Commission (the "SEC"), such as market risk, liquidity risk, competitive risk, regulatory risk and other commonly recognized forms of risk relating to Microbot and its securities. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this document might not occur. Microbot is not obligated to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of Microbot's securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

## SURGICAL ROBOTICS TODAY

- Large, cumbersome footprint
- Dedicated room, dedicated staff
- Time consuming to set up and use
- Long and expensive learning curve

# ENDO-VASCULAR: TOTAL ADDRESSABLE MARKET (US)




[1] Medtech 360 Reports


MULTIPLE BARRIERS LEADING TO LOW PENETRATION
Special training, long learning curve
Cumbersome and expensive disposables
Extended set-up time
Dedicated infrastructure
Large footprint
Capital expense
5M+
Coronary
Peripheral
Neuro
1 Meditech 360 Reports
2 Deduced from Public Records

# MULTIPLE BARRIERS LEADING TO LOW PENETRATION

- User friendly
- No additional disposables
- Sterile Kit
- No dedicated infrastructure
- Small footprint
- Fully disposable

liberty
microbot medical


1 Medtech 360 Reports
2 Deduced from Public Records

The LIBERTY system is not cleared for marketing or any clinical use


ELIMINATING BARRIERS, ALLOWING ACCESS


ACCESSIBILITY: THE FUTURE OF SURGICAL ROBOTICS
ACCESS-ABILITY


ACCESS-ABILITY FOR ALL™
PHYSICIANS
PATIENTS
HOSPITAL
HOSPITALS
HEALTH CARE (PAYER)
NO MATTER WHAT • NO MATTER WHERE • NO MATTER WHO

"I'm **very, very pleased** with the first experience; it's an easy setup of the system."

"For [the] young generation, it would probably be **easier to do with the robot** than to do it manually."

**Dr. Dmitry J. Rabkin**
*Vascular & Interventional Radiology*

"Would probably **greatly enhance** the use of certain applications."

"To be able to navigate very precisely in a short time…**This is something which will prop up the performance of our fellows** that suddenly can reach the target very quickly."

**Dr. Sebastian Flacke**
*Radiology and Interventional Radiology*

"Sitting at the console outside in the control room and navigating the microcatheter and the wire into the neurovascular system was **impressive**."

"If I would have this system today . . . **I would definitely make use of it**."

**Dr. Ajay K. Wakhloo**
*Interventional Neuroradiology*

The LIBERTY system is not cleared for marketing or any clinical use


ROAD TO COMMERCIALIZATION
Pre-Submission
Finalize U.S. Food and Drug Administration (FDA) pre-submission for the LIBERTY® Robotic System
Trials
Initiate pre-clinical trial for LIBERTY® Robotic System in Q3 of 2022
Pending FDA feedback, clinical trial process to commence in Q4 2022
Key Opinion Leaders
Continue to engage with Key Opinion Leaders (KOLs) and leading academic centers to educate and raise awareness of the LIBERTY® Robotic System
Commercialization Readiness
Establish a strong network of centers of excellence in US, Europe and Israel in anticipation of commercial launch
IP Portfolio
Expand and protect the Company's global IP portfolio in global jurisdictions, which creates significant barriers to entry
Pipeline Development
Continue developing LIBERTY® ecosystem to include instruments (one-and-done), big data, etc.
Enhance Core Capabilities
Continue establishing leadership team to support future regulatory and commercial activities
stryker®
Continued collaboration for dedicated neurovascular kits